Tesamorelin: The FDA-Approved Peptide for Metabolic Health
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) and the only compound in its class to receive FDA approval. Originally approved in 2010 for treating excess abdominal fat in adults with HIV-associated lipodystrophy, it has since been studied for broader metabolic applications including non-alcoholic fatty liver disease, cognitive decline, and body composition in aging adults. Its approved status makes it a clinically distinct option in a field dominated by investigational compounds.
What Is Tesamorelin?
Tesamorelin (brand name: Egrifta) is a 44-amino acid GHRH analogue. Like sermorelin and CJC-1295, it works by binding to GHRH receptors in the pituitary gland and stimulating the pulsatile release of growth hormone. What distinguishes tesamorelin is its clinical development history: it went through the full FDA approval process, generating controlled trial data in human subjects that most therapeutic peptides lack.
It was approved by the FDA in 2010 under the brand name Egrifta for reducing excess visceral abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. HIV-associated lipodystrophy — a redistribution of body fat driven by both the virus and certain medications — was the clinical context that brought tesamorelin through trials, but the mechanisms driving its effects are relevant to a much wider population.
How Does Tesamorelin Work?
Tesamorelin stimulates the pituitary to release growth hormone through the GHRH pathway. The downstream effects follow the standard growth hormone axis:
Growth hormone release. Tesamorelin produces pulsatile GH release that maintains the natural physiological rhythm, unlike direct GH injection which produces supraphysiological levels.
IGF-1 elevation. Released growth hormone drives IGF-1 production in the liver, which mediates many of growth hormone's downstream metabolic effects.
Lipolysis. Growth hormone is a potent lipolytic hormone — it mobilizes stored fat for use as energy. The visceral fat reduction seen in tesamorelin trials is mediated through this pathway.
Hepatic fat reduction. A 2026 study in Obesity Research and Clinical Practice (PMID: 41545261) found that tesamorelin produced significant improvements in body composition, hepatic fat, and metabolic markers — confirming effects beyond visceral fat reduction that extend to liver health.
What Does the Research Show?
HIV lipodystrophy (FDA-approved indication)
The Phase 3 LIPO trials that supported FDA approval demonstrated that tesamorelin reduced visceral adipose tissue (VAT) by approximately 15-18% compared to placebo over 26 weeks in adults with HIV-associated lipodystrophy. These reductions were sustained with continued treatment and reversed upon discontinuation — consistent with the mechanism of ongoing GH stimulation.
Liver health
HIV-positive patients have elevated rates of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NASH). A 2025 review in Current Opinion in HIV and AIDS examined tesamorelin specifically for this application, and the 2026 Obesity Research study confirmed improvements in hepatic fat alongside body composition changes. Tesamorelin is one of the few compounds showing liver fat reduction alongside visceral fat reduction in clinical data.
Cognitive effects
Several studies have examined tesamorelin's effects on cognitive function in aging adults and in HIV-positive populations with cognitive impairment. Growth hormone and IGF-1 play roles in brain function, and research from Johns Hopkins has found that tesamorelin improved verbal memory and executive function in older adults with mild cognitive impairment — an unexpected application that broadened clinical interest.
Body composition in aging adults
Off-label clinical use of tesamorelin for age-related metabolic decline follows the same rationale as other GHRH analogues — restoring more youthful growth hormone pulsatility to counter the visceral fat accumulation and lean mass loss associated with aging. The existing trial data provides a stronger evidence base for this application than most investigational GHRH analogues have.
How Does Tesamorelin Compare to Other Growth Hormone Secretagogues?
| Tesamorelin | Sermorelin | CJC-1295/Ipamorelin | |
|---|---|---|---|
| Mechanism | GHRH analogue | GHRH analogue | GHRH + GHSR dual |
| FDA approval | Yes (HIV lipodystrophy) | No (withdrawn commercially) | No |
| Half-life | ~26 min | ~11 min | Days (CJC) / 2h (ipa) |
| Clinical trial data | Extensive (Phase 3) | Limited human data | Limited human data |
| Primary application | Visceral fat, liver health | General GH optimization | GH optimization |
Tesamorelin's key differentiator is the Phase 3 data. For patients who want evidence-based growth hormone therapy with clinical trial support, it offers a stronger foundation than most alternatives.
Who Is Tesamorelin For?
FDA-approved use: Adults with HIV-associated lipodystrophy who have excess visceral abdominal fat as a consequence of antiretroviral therapy.
Clinical interest extends to:
- Adults with significant visceral adiposity and metabolic syndrome features
- Patients with elevated hepatic fat (fatty liver) alongside metabolic dysfunction
- Older adults experiencing cognitive decline where IGF-1 optimization is part of the clinical strategy
- Patients who specifically want the stronger evidence base of an FDA-studied compound
Tesamorelin is available by prescription and can be compounded through licensed 503A pharmacies for off-label applications.
What Are the Side Effects?
Tesamorelin's side effect profile reflects its growth hormone-stimulating mechanism:
- Fluid retention and edema — particularly in early weeks of treatment as growth hormone levels rise
- Joint and muscle discomfort — a common growth hormone class effect, usually dose-dependent
- Injection site reactions — redness, itching, or discomfort at the injection site
- Elevated blood glucose — growth hormone reduces insulin sensitivity; glucose monitoring is appropriate, particularly in patients at risk for diabetes
- Carpal tunnel symptoms — fluid shifts can cause transient hand tingling; reduces with dose adjustment
The FDA label from the clinical trials provides detailed safety data — a significant advantage over compounds where human safety data is thin.
Frequently Asked Questions
Is tesamorelin only for people with HIV?
The FDA approval is specifically for HIV-associated lipodystrophy, but clinical use extends beyond this indication. Providers prescribe tesamorelin off-label for visceral fat reduction, liver health support, and cognitive applications in patients without HIV. A provider familiar with metabolic peptide therapy can assess whether tesamorelin fits your clinical picture.
How is tesamorelin different from HGH?
Tesamorelin stimulates your own pituitary to release growth hormone — the natural regulatory axis remains intact and physiological feedback mechanisms continue to operate. Exogenous HGH bypasses this entirely, introducing synthetic hormone directly and suppressing your own production. Tesamorelin maintains more physiological growth hormone patterns with a lower risk of overexposure.
How long does tesamorelin take to work?
Clinical trials showed measurable visceral fat reduction by 26 weeks. In practice, IGF-1 levels respond within 4-6 weeks, providing an early biochemical confirmation of response. Symptom-level changes — energy, sleep, body composition — typically emerge over 2-3 months.
Does visceral fat return after stopping tesamorelin?
Yes. The LIPO trial data showed that visceral fat reduction reversed after discontinuation. Tesamorelin manages the hormonal environment that drives fat accumulation; stopping it removes that management. Long-term use is required for sustained effect.
Is tesamorelin covered by insurance?
For the FDA-approved HIV indication, coverage is typically available through specialty pharmacy benefits. Off-label compounded use is typically not covered by insurance. Cost varies by provider and pharmacy.
Sources
- Falutz J, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin. *Obes Res Clin Pract.* 2026.
- Johansson E, et al. Metabolic dysfunction-associated steatotic liver disease in people with HIV. *Curr Opin HIV AIDS.* 2025.
- Stanley TL, et al. Tesamorelin decreases liver fat and liver enzymes in HIV-infected patients with abdominal fat accumulation. *AIDS.* 2012.
- Shi L, et al. Effects of tesamorelin on cognitive function in HIV-positive patients. *Clin Infect Dis.* 2017.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *N Engl J Med.* 2007.
This content is for educational purposes only and does not constitute medical advice. Peptide therapies should only be pursued under the supervision of a licensed healthcare provider. Amino Clinic recommends consulting with your physician before starting any new therapy.
